Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy

BACKGROUND: Drug combinations of the proteasome inhibitor bortezomib with cytotoxic chemotherapy are currently evaluated in phase 2 and 3 trials for the treatment of paediatric acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL). METHODS: We investigated whether expression ratios of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Hematol Oncol
Egile Nagusiak: Niewerth, Denise, Kaspers, Gertjan J. L., Jansen, Gerrit, van Meerloo, Johan, Zweegman, Sonja, Jenkins, Gaye, Whitlock, James A., Hunger, Stephen P., Lu, Xiaomin, Alonzo, Todd A., van de Ven, Peter M., Horton, Terzah M., Cloos, Jacqueline
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2016
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5011854/
https://ncbi.nlm.nih.gov/pubmed/27599459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0312-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak